How the LDT Final Rule’s Exemptions Apply to Oncology Labs
Regulatory expert explores whether any exclusions might benefit cancer laboratories trying to navigate upcoming compliance deadlines
Regulatory expert explores whether any exclusions might benefit cancer laboratories trying to navigate upcoming compliance deadlines
The year was certainly an interesting one in terms of regulatory change in the medical laboratory space.
A decline in COVID-19 testing demand, along with a challenging economy, made for a difficult quarter for diagnostics companies.
Having twice failed to disrupt health care, Amazon opts for a different strategy this time around—and it may just work.
A high volume of FDA approvals for new tests and diagnostic products made up for the relatively low number of approvals in the EU.
Automating travel and expense significantly improves performance, but adding mobility takes such improvements to a much higher level.
The recent FDA approval of an OTC test shows that COVID-19 saliva testing may be poised for bigger and better things in the years ahead.
Though only seven transactions were announced or closed in November, two were billion-dollar deals.
Key cases over the past month were the usual FCA-related fare, apart from a dismissed sex discrimination case.
It’s important to have a clear policy in place for approving remote work requests and ensuring employees remain productive.
Federal enforcement actions at the end of October and first two weeks of November featured some unusual characters.